You are leaving Smmttx.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible
for its contents.

Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.

To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.

A phase II study of AK112 (PD-1/VEGF Bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

A phase II study of AK112 (PD-1/VEGF Bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)